WO2001064751A3 - High potency recombinant antibodies and method for producing them - Google Patents

High potency recombinant antibodies and method for producing them Download PDF

Info

Publication number
WO2001064751A3
WO2001064751A3 PCT/US2001/006815 US0106815W WO0164751A3 WO 2001064751 A3 WO2001064751 A3 WO 2001064751A3 US 0106815 W US0106815 W US 0106815W WO 0164751 A3 WO0164751 A3 WO 0164751A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
neutralizing
high potency
disclosed
producing
Prior art date
Application number
PCT/US2001/006815
Other languages
French (fr)
Other versions
WO2001064751A2 (en
Inventor
James F Young
Scott Koenig
Leslie S Johnson
William D Huse
Herren Wu
Jeffry D Watkins
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001564244A priority Critical patent/JP2003525061A/en
Application filed by Medimmune Inc filed Critical Medimmune Inc
Priority to ES01914657T priority patent/ES2390761T3/en
Priority to AU2001240020A priority patent/AU2001240020B9/en
Priority to CA002401652A priority patent/CA2401652A1/en
Priority to EP01914657A priority patent/EP1259547B1/en
Priority to AU4002001A priority patent/AU4002001A/en
Priority to DK01914657.0T priority patent/DK1259547T3/en
Publication of WO2001064751A2 publication Critical patent/WO2001064751A2/en
Publication of WO2001064751A3 publication Critical patent/WO2001064751A3/en
Priority to AU2006203134A priority patent/AU2006203134B2/en
Priority to AU2007202040A priority patent/AU2007202040B2/en
Priority to AU2010202006A priority patent/AU2010202006B2/en
Priority to AU2010219289A priority patent/AU2010219289B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Abstract

High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for production high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
PCT/US2001/006815 2000-01-27 2001-03-01 High potency recombinant antibodies and method for producing them WO2001064751A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU4002001A AU4002001A (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
ES01914657T ES2390761T3 (en) 2000-03-01 2001-03-01 Recombinant high-potency antibodies and method for their production
AU2001240020A AU2001240020B9 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
CA002401652A CA2401652A1 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
EP01914657A EP1259547B1 (en) 2000-03-01 2001-03-01 High potency recombinant antibodies and method for producing them
JP2001564244A JP2003525061A (en) 2000-03-01 2001-03-01 High potency recombinant antibody and method for producing the same
DK01914657.0T DK1259547T3 (en) 2000-03-01 2001-03-01 HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
AU2006203134A AU2006203134B2 (en) 2000-01-27 2006-07-21 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2007202040A AU2007202040B2 (en) 2000-03-01 2007-05-08 High potency recombinant antibodies and method for producing them
AU2010202006A AU2010202006B2 (en) 2000-01-27 2010-05-18 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2010219289A AU2010219289B2 (en) 2000-03-01 2010-09-03 High potency recombinant antibodies and method for producing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18625200P 2000-03-01 2000-03-01
US60/186,252 2000-03-01

Publications (2)

Publication Number Publication Date
WO2001064751A2 WO2001064751A2 (en) 2001-09-07
WO2001064751A3 true WO2001064751A3 (en) 2001-12-20

Family

ID=22684221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006815 WO2001064751A2 (en) 2000-01-27 2001-03-01 High potency recombinant antibodies and method for producing them

Country Status (10)

Country Link
US (2) US7700735B2 (en)
EP (3) EP2341074A1 (en)
JP (2) JP2003525061A (en)
AU (4) AU2001240020B9 (en)
CA (1) CA2401652A1 (en)
CY (1) CY1113298T1 (en)
DK (1) DK1259547T3 (en)
ES (1) ES2390761T3 (en)
PT (1) PT1259547E (en)
WO (1) WO2001064751A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002219944B2 (en) * 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
ES2390761T3 (en) 2000-03-01 2012-11-16 Medimmune, Llc Recombinant high-potency antibodies and method for their production
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2341060B1 (en) * 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2466025A1 (en) * 2001-11-02 2003-08-07 Centocor, Inc. Rsv proteins, antibodies, compositions, methods and uses
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7714113B2 (en) * 2002-02-13 2010-05-11 Ludwig Institute For Cancer Research Fusion proteins of humanized g250 specific antibodies and uses thereof
JP4557714B2 (en) * 2002-05-10 2010-10-06 メディミューン，エルエルシー EphA2 monoclonal antibody and method of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
CN1780855B (en) 2003-01-24 2011-03-30 应用分子进化公司 Human il-1 beta antagonists
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US20100166746A1 (en) * 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
JP2010534057A (en) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ Recombinant antibody for treating respiratory syncytial virus infection
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2466916T3 (en) 2007-06-27 2014-06-11 Admune Therapeutics Llc IL-15 and IL-15R alpha complexes and uses thereof
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
SG10201407519TA (en) * 2009-11-19 2015-01-29 Univ Singapore Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
BR112012025593A2 (en) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
HUE049154T2 (en) 2011-05-04 2020-09-28 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
CN103957935B (en) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 Anti- CGRP or anti-CGRP R antibody or antibody fragment are used to treat or prevent the chronic and diarrhoea of acute form purposes
KR102098546B1 (en) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN108373502B (en) 2011-05-20 2022-03-22 H.伦德贝克公司 anti-CGRP compositions and uses thereof
TWI659968B (en) 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
DK3387019T3 (en) 2015-12-09 2022-01-10 Scripps Research Inst RELAXIN-IMMUNOGLOBULIN INFUSION PROTEINS AND METHODS OF USE
IL303833A (en) 2016-10-21 2023-08-01 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP7265984B2 (en) 2016-10-21 2023-04-27 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods of their production and use
EP3529270A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005229A1 (en) * 1994-08-15 1996-02-22 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1188985A (en) 1980-07-01 1985-06-18 Edward J. Stott Production of viral antigens
DE3235924T1 (en) 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire MONOCLONAL ANTIBODY
ATE37983T1 (en) * 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
US5340926A (en) 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US5332805A (en) 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2590674B1 (en) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med NEW DIAGNOSTIC REAGENTS
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8719041D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4916893A (en) * 1987-09-02 1990-04-17 Sundstrand Corporation Multipurpose auxiliary power unit
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
DE3878468T2 (en) 1987-12-23 1993-06-09 Upjohn Co CHIMARENE GLYCOPROTEINS, CONTAINING IMMUNOGENIC SEGMENTS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS.
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
JPH01268646A (en) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd Antitumor agent
US5137804A (en) 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
JP2571874B2 (en) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド Protein microsphere composition
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5279935A (en) 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
JPH04507109A (en) 1990-05-03 1992-12-10 システミックス　インコーポレイテッド Human lymphoid tissue in immunocompromised hosts
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
DE69233750D1 (en) * 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
ES2113428T3 (en) 1991-04-22 1998-05-01 Massachusetts Health Res SCREENING PROCESS OF PLASMA SAMPLES TO DETERMINE ANTIBODY TITLES EFFECTIVE AGAINST RESPIRATORY VIRUSES.
JPH06507404A (en) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン How to treat infectious respiratory diseases
CA2044940A1 (en) 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
JP3253300B2 (en) * 1991-11-15 2002-02-04 コーネル リサーチ ファウンデイション インコーポレイテッド Indirect immunoassay for dioxin analogs
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6685942B1 (en) * 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5424189A (en) 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5538952A (en) 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A (en) 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE69609188T2 (en) * 1995-09-18 2000-12-21 Intracel Corp NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
FR2758331B1 (en) 1997-01-14 1999-03-05 Univ Bourgogne NEW MEANS FOR DIAGNOSIS, PREVENTION AND TREATMENT FOR CONTAMINATION OR INFECTIONS WITH MUCOUS TROPISM VIRUSES
US6117980A (en) * 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7229619B1 (en) * 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
ES2390761T3 (en) 2000-03-01 2012-11-16 Medimmune, Llc Recombinant high-potency antibodies and method for their production
US6565849B2 (en) * 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
CA2407292A1 (en) * 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
US20020004046A1 (en) * 2000-05-03 2002-01-10 Johnson Leslie S. Combination therapy of respiratory diseases using antibodies
EP1152199B1 (en) 2000-05-03 2005-07-27 IPV Inheidener Produktions- und Vertriebsgesellschaft mbH Thermal container
AU2001263443A1 (en) * 2000-05-25 2001-12-03 Med Immune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
JP5490972B2 (en) * 2000-08-04 2014-05-14 中外製薬株式会社 Protein injection formulation
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas
WO1996005229A1 (en) * 1994-08-15 1996-02-22 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEFTA L J F ET AL: "Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs", IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 49 - 57, XP004127386, ISSN: 1380-2933 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY,LONDON,GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP000978702, ISSN: 0022-2836 *
YANG W -P ET AL: "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 254, 1995, pages 392 - 403, XP000199739, ISSN: 0022-2836 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Also Published As

Publication number Publication date
EP1259547A2 (en) 2002-11-27
AU2001240020B2 (en) 2007-02-08
US8153133B2 (en) 2012-04-10
AU2007202040A1 (en) 2007-05-24
JP2010162025A (en) 2010-07-29
EP1259547B1 (en) 2012-07-11
JP2003525061A (en) 2003-08-26
EP2341075A1 (en) 2011-07-06
CA2401652A1 (en) 2001-09-07
CY1113298T1 (en) 2016-04-13
EP2341074A1 (en) 2011-07-06
DK1259547T3 (en) 2012-10-15
AU2010219289A1 (en) 2010-09-30
US20020098189A1 (en) 2002-07-25
US20100239574A1 (en) 2010-09-23
AU4002001A (en) 2001-09-12
PT1259547E (en) 2012-10-15
US7700735B2 (en) 2010-04-20
AU2007202040B2 (en) 2010-06-10
AU2001240020B9 (en) 2008-12-04
WO2001064751A2 (en) 2001-09-07
AU2010219289B2 (en) 2012-05-10
ES2390761T3 (en) 2012-11-16

Similar Documents

Publication Publication Date Title
WO2001064751A3 (en) High potency recombinant antibodies and method for producing them
ATE402192T1 (en) ANTI-CCR4 ANTIBODIES AND FRAGMENTS THEREOF
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
IL128014A (en) Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2002024887A3 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
WO2005061537A3 (en) Squamous cell carcinoma antigens and use thereof
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
HU9300349D0 (en) Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them
WO2001075015A3 (en) A novel polypeptide, fat24 and the polynucleotide encoding the polypeptide
WO2001036979A3 (en) Placental human neurokinin b precursor
WO2001075039A3 (en) A novel polypeptide, human rna helicase 10 and the polynucleotide encoding the polypeptide
WO2001075061A3 (en) A novel polypeptide, cdv-1-42 and the polynucleotide encoding the polypeptide
WO2001083675A3 (en) A novel polypeptide, a atp-dependent human hydrolase serine 10.2 and the polynucleotide encoding the polypeptide
WO2001075021A3 (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
WO2001075006A3 (en) A novel poypeptide, light chain of protein lattice 37 and the polynucleotide encoding the polypeptide
WO2001075036A3 (en) A novel polypeptide, human immunophiline 14 and the polynucleotide encoding the polypeptide
WO2001075051A3 (en) A novel polypeptide, a human stroma antigen 3 protein 17 and the polynucleotide encoding the polypeptide
WO2001075016A3 (en) A novel polypeptide, a human tyrosinase 16, and the polynucleotide encoding the polypeptide
WO2001075042A3 (en) A novel polypeptide, atp-dependent human hydrolase serine 9 and the polynucleotide encoding the polypeptide
WO2002000831A3 (en) A novel polypeptide, a bromine group domain 12 and the polynucleotide encoding the polypeptide
WO2001075056A3 (en) A novel polypeptide, human light-chain clathrine 20 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001240020

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001914657

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2401652

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 564244

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001914657

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642